HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
about
The Road Less Traveled: HIV's Use of Alternative Routes through Cellular PathwaysA Single-Cell Platform for Monitoring Viral Proteolytic Cleavage in Different Cellular CompartmentsFunctional and structural characterization of the integrase from the prototype foamy virusStructure-Based Design, Synthesis, and Structure−Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating PhenyloxazolidinonesCrystallographic and Functional Analysis of the ESCRT-I /HIV-1 Gag PTAP InteractionPotent Antiviral HIV-1 Protease Inhibitor GRL-02031 Adapts to the Structures of Drug Resistant Mutants with Its P1′-Pyrrolidinone RingHIV-1 Protease-Substrate Coevolution in Nelfinavir ResistanceEffects of Hinge Region Natural Polymorphisms on Human Immunodeficiency Virus-1 Protease Structure, Dynamics and Drug-Pressure EvolutionOnly slight impact of predicted replicative capacity for therapy response predictionPrevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter CohortNational prevalence and trends of HIV transmitted drug resistance in MexicoIdentification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitroSignificantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram dataHIV-1 pol diversity among female bar and hotel workers in Northern TanzaniaIntegrated analysis of residue coevolution and protein structures capture key protein sectors in HIV-1 proteinsTrends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, MozambiqueStrong Selection Significantly Increases Epistatic Interactions in the Long-Term Evolution of a ProteinMinor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsAdaptive evolution by recombination is not associated with increased mutation rates in Maize streak virus.Host sequence motifs shared by HIV predict response to antiretroviral therapyPairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease.Transmitted drug resistance in nonsubtype B HIV-1 infection.Inhibition of HIV-1 replication by isoxazolidine and isoxazole sulfonamides.Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies.Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans.Inference of Epistatic Effects Leading to Entrenchment and Drug Resistance in HIV-1 Protease.Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, MozambiqueCombination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine CohortCo-lethality studied as an asset against viral drug escape: the HIV protease case.Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations.HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in AsiaInhibitory effect of aqueous Dandelion extract on HIV-1 replication and reverse transcriptase activityA flavonoid, luteolin, cripples HIV-1 by abrogation of tat function.A multifaceted analysis of HIV-1 protease multidrug resistance phenotypesSecondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II.
P2860
Q27027607-D70DFDDD-C8F6-4777-8A2F-4CBE97A2B005Q27468663-4B12C3EB-3D8E-427A-92D6-B924180BCB43Q27653000-98D36AD4-71F8-4B15-A841-1E097A8ED75CQ27665164-9D989C1F-5CF2-4195-AF67-22748FA5395BQ27665841-B1914CE2-03CE-4995-8E47-59B3F059ACA9Q27677939-A7B3943A-07BD-4B80-A5F5-0B766A368EC1Q27683192-345904B6-FEE1-411A-8D90-05122FD9E62FQ27727967-FD493536-4BC8-44B9-B493-C0DB5548E548Q28472749-83CDC40D-EB66-48FC-9FFC-9EC8C21F975BQ28475698-77DC0138-3838-48E8-A011-DB1542FEE6F9Q28477977-C4E40FD9-4EA8-4D2E-9493-95740753F83AQ28483726-6B9907D1-1567-4165-BBD3-FB1863614725Q28486299-9C823DCF-70FA-412A-932C-044354F76B95Q28540536-B6D0E068-3951-4EBE-A1E7-53778158736BQ28543396-E256131E-EB29-4C22-8E8E-50E41A795800Q28546341-7E22FE5F-A767-43C6-A773-73E9E3D5C7C3Q28551065-D1F2C677-DF68-4CF9-99E9-BDA532F5BF9EQ28728304-865703F0-DEBD-4BF2-8667-26B64B9C2E04Q31109744-75A8AF23-9E8C-42A1-B201-D6893469B25FQ33486144-58F69F24-40C3-4CCA-9A69-13949AFB1B3FQ33503921-DE8DDA03-C032-45F4-B701-30D0A72E5760Q33567164-45046BF4-80A1-4561-8532-2D0EE61A1F82Q33582517-638DF474-3F33-4335-92AA-83547F471D35Q33601530-AF3C20C2-F4FE-49AC-8B0D-73504D4CD936Q33624190-18C474BA-AC60-448C-8158-8819C81A17B9Q33645217-98E6EB97-28AF-4B02-A360-8CDCE8C407C6Q33668468-56C29BAA-D4C8-4E5F-AF50-940767487527Q33698683-BC4AD8BF-2C8D-47DE-8F72-A706C20D27A2Q33713862-61507ACC-A119-48EB-93F0-2E79418AA8B2Q33768822-A56E6CCA-7D91-4B7B-8936-424F8AD3C781Q33902540-17CF57F5-5430-4FB3-B1AB-CE5F3448717DQ33910771-114B8615-BAAB-4915-8B83-DC252199F709Q33968760-69B75411-E01F-461E-B157-B88DC30459EDQ34038440-757EBA42-3985-40EF-B2FA-D75CEC9C4E3AQ34072721-F81041AE-35D6-4DF9-AEDC-510E1033FA4BQ34073041-CBF08490-1F7C-4D9E-AF56-7656B2F732A3Q34091121-E1F3D4AE-DA21-4A2D-B4DC-F518C481C338Q34102058-12DADB74-91E3-42DD-B61D-1B32733CD468Q34108775-30FA4802-CBD9-4227-BD55-9497D430AA1AQ34207464-7A8FBAB3-4ACE-4077-B915-757D33561B76
P2860
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
@en
type
label
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
@en
prefLabel
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
@en
P2860
P1433
P1476
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
@en
P2093
Jonathan M Schapiro
Robert W Shafer
P2860
P577
2008-04-01T00:00:00Z